Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
RAMP 203
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
- NCT05074810 ↗
- Active, not recruiting
- Verastem, Inc.
- Focused
We haven't built an HCP commentary report on RAMP 203 (avutometinib plus sotorasib; avutometinib plus sotorasib plus defactinib in KRAS G12C mutant non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RAMP 203 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Non Small Cell Lung Cancer; KRAS Activating Mutation
- Interventions
- avutometinib and sotorasib; avutometinib and sotorasib and defactinib
- Arms
- avutometinib (VS-6766)+sotorasib · Experimental
- avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve · Experimental
- avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed · Experimental
- avutometinib (VS-6766)+sotorasib+defactinib · Experimental
- avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive · Experimental
- avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed · Experimental
- Enrollment
- 153 (estimated)
- Primary outcomes
- Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinib
- Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part A
- Sponsor
- Verastem, Inc. with Amgen
- Start
- Apr 12, 2022
- Primary completion
- Jun 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05074810 · updated Jan 12, 2026
Publications
linked from the registry- Coma S, Musteanu M, Malvezzi CC, Jamieson RR, Patrucco E, Mira A, Dilly J, Li Z, Fernandez-Rodriguez A, Lopez-Garcia A, Aguirre AJ, Barbacid M, Ambrogio C, Pachter JA. FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. Sci Transl Med. 2026 Sep 30;18(869):eaea4608. doi: 10.1126/scitranslmed.aea4608. Epub 2026 Sep 30. PubMed 42814800